Trials
5 active
6 in total · 5 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants receive Visugromab (recommended dose) intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.”In the company’s words, NCT07098988 on ClinicalTrials.gov
- Tested for
- Metastatic Non-Squamous Non-Small Cell Lung Cancer (2 trials), Adult Solid Tumor (2 trials), Cancer-associated Cachexia, Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound, Solid Tumor, Adult
- Main trialPhase 2/3
- “A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4…”In the company’s words, NCT07112196 on ClinicalTrials.gov
- Other names
- CTL-002
Other drugs for Metastatic Non-Squamous Non-Small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up5
- 30 Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Mar 2029Phase 2 trial completes · ClinicalTrials.gov
- Sep 2029Phase 2 trial completes · ClinicalTrials.gov
- 1 Oct 2029Phase 2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Dec 2029 | Visugromab in Cachexia International Trial | |
| Phase 2Recruiting | 31 Mar 2029 | Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | |
| Phase 2Recruiting | Sep 2029 | Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure | |
| Phase 2Recruiting | 1 Oct 2029 | Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC | |
| Phase 1/2Active, not recruiting | 30 Apr 2028 | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER) | |
| Phase 2Completed | 16 Oct 2025 | Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026